163 related articles for article (PubMed ID: 18507843)
21. Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori, and proton pump inhibitor therapy.
Weber HC; Venzon DJ; Jensen RT; Metz DC
Gastroenterology; 1997 Jan; 112(1):84-91. PubMed ID: 8978346
[TBL] [Abstract][Full Text] [Related]
22. [Comparative efficacy of lansoprazole and omeprazole on the intragastric pH measured over a period of 24 hours and on the basal].
Paul G; Ramdani A; Mignon M; Vallot T; Forestier S; Cadiot G; Ruszniewski P; Joubert-Collin M
Gastroenterol Clin Biol; 1994; 18(8-9):695-701. PubMed ID: 7875436
[TBL] [Abstract][Full Text] [Related]
23. Zollinger Ellison syndrome, treated with lansoprazole, during pregnancy.
Mayer A; Sheiner E; Holcberg G
Arch Gynecol Obstet; 2007 Aug; 276(2):171-3. PubMed ID: 17318560
[TBL] [Abstract][Full Text] [Related]
24. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion.
Metz DC; Soffer E; Forsmark CE; Cryer B; Chey W; Bochenek W; Pisegna JR
Am J Gastroenterol; 2003 Feb; 98(2):301-7. PubMed ID: 12591045
[TBL] [Abstract][Full Text] [Related]
25. Costs and risks in the management of patients with gastric acid hypersecretion.
Hirschowitz BI; Fineberg N; Wilcox CM; Mohnen J; Worthington J
J Clin Gastroenterol; 2010 Jan; 44(1):28-33. PubMed ID: 19581810
[TBL] [Abstract][Full Text] [Related]
26. The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome.
Nieto JM; Pisegna JR
Expert Opin Pharmacother; 2006 Feb; 7(2):169-75. PubMed ID: 16433582
[TBL] [Abstract][Full Text] [Related]
27. Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia.
Hirschowitz BI; Worthington J; Mohnen J; Haber M
Aliment Pharmacol Ther; 2007 Sep; 26(6):869-78. PubMed ID: 17767471
[TBL] [Abstract][Full Text] [Related]
28. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
Langtry HD; Wilde MI
Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
[TBL] [Abstract][Full Text] [Related]
29. Present experiences with omeprazole in the Zollinger-Ellison syndrome.
Lamers CB
Scand J Gastroenterol Suppl; 1986; 118():123-8. PubMed ID: 3460167
[TBL] [Abstract][Full Text] [Related]
30. Nasogastric lansoprazole is effective in suppressing gastric acid secretion in critically ill patients.
Tsai WL; Poon SK; Yu HK; Chang CS; Yeh HZ; Ko CW; Chen GH
Aliment Pharmacol Ther; 2000 Jan; 14(1):123-7. PubMed ID: 10632655
[TBL] [Abstract][Full Text] [Related]
31. Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome.
McArthur KE; Collen MJ; Maton PN; Cherner JA; Howard JM; Ciarleglio CA; Cornelius MJ; Jensen RT; Gardner JD
Gastroenterology; 1985 Apr; 88(4):939-44. PubMed ID: 3972233
[TBL] [Abstract][Full Text] [Related]
32. [Effectiveness and safety of lansoprazole in the treatment of Zollinger-Ellison syndrome. First six months of treatment].
Pospaï D; Cadiot G; Forestier S; Ruszniewski P; Coste T; Escourrou J; Mignon M; Gresze
Gastroenterol Clin Biol; 1998 Oct; 22(10):801-8. PubMed ID: 9854205
[TBL] [Abstract][Full Text] [Related]
33. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors.
Hirschowitz BI; Worthington J; Mohnen J
Aliment Pharmacol Ther; 2008 Jun; 27(11):1110-21. PubMed ID: 18315582
[TBL] [Abstract][Full Text] [Related]
34. An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.
Morocutti A; Merrouche M; Bjaaland T; Humphries T; Mignon M
Aliment Pharmacol Ther; 2006 Nov; 24(10):1439-44. PubMed ID: 17081164
[TBL] [Abstract][Full Text] [Related]
35. A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome.
Termanini B; Gibril F; Stewart CA; Weber HC; Jensen RT
Aliment Pharmacol Ther; 1996 Feb; 10(1):61-71. PubMed ID: 8871445
[TBL] [Abstract][Full Text] [Related]
36. [Proton pump blockers and their significance in gastroenterology].
Dítĕ P; Prásek J
Vnitr Lek; 1995 Aug; 41(8):549-54. PubMed ID: 7483340
[TBL] [Abstract][Full Text] [Related]
37. Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma.
Jensen RT; Fraker DL
JAMA; 1994 May; 271(18):1429-35. PubMed ID: 7513768
[No Abstract] [Full Text] [Related]
38. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome.
Pisegna JR; Norton JA; Slimak GG; Metz DC; Maton PN; Gardner JD; Jensen RT
Gastroenterology; 1992 Mar; 102(3):767-78. PubMed ID: 1537514
[TBL] [Abstract][Full Text] [Related]
39. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
Clissold SP; Campoli-Richards DM
Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
[TBL] [Abstract][Full Text] [Related]
40. Rabeprazole for the treatment of acid-related disorders.
Marelli S; Pace F
Expert Rev Gastroenterol Hepatol; 2012 Aug; 6(4):423-35. PubMed ID: 22928894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
